Skip to main content

Complex Regional Pain Syndrome Type I

1
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Ambros Therapeutics
1 program
1
neridronatePhase 32 trials
Active Trials
NCT07857733Recruiting135Est. Feb 2029
NCT07210515Recruiting270Est. Jan 2028
Abbott
AbbottABBOTT PARK, IL
1 program
Implantable spinal cord stimulatorN/A1 trial
Active Trials
NCT05877612Unknown30Est. Sep 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
Ambros Therapeuticsneridronate
Ambros Therapeuticsneridronate
AbbottImplantable spinal cord stimulator

Clinical Trials (3)

Total enrollment: 435 patients across 3 trials

NCT07857733Ambros Therapeuticsneridronate

Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1

Start: Oct 2026Est. completion: Feb 2029135 patients
Phase 3Recruiting
NCT07210515Ambros Therapeuticsneridronate

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

Start: Apr 2026Est. completion: Jan 2028270 patients
Phase 3Recruiting
NCT05877612AbbottImplantable spinal cord stimulator

Efficacy of Spinal Cord Stimulation in Burst Mode in the Treatment of Complex Regional Pain Syndromes Type 1 of the Upper Limbs

Start: Sep 2023Est. completion: Sep 202530 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 435 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.